Mesalamine

Lialda is labeled for induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis and treatment in pediatric patients weighing at least 24 kg. Apriso is for maintenance of adult ulcerative-colitis remission, not a labeled induction regimen. Pentasa is for adult induction of remission and treatment of mildly to moderately active ulcerative colitis.

Canasa treats mildly to moderately active ulcerative proctitis in adults. Rowasa treats active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. The selected rectal labels do not establish pediatric effectiveness.

This profile reviews Lialda, Apriso, Pentasa, Canasa and Rowasa. Other 400/800 mg delayed-release products, Delzicol, Asacol HD, sulfite-free enemas, other-country products and compounded preparations need their own current labeling and availability verification. Selected labels do not establish Crohn disease treatment. Do not substitute oral release systems or rectal forms using only total milligrams.

Shake Rowasa to make a homogeneous suspension, remove the protective sheath and lie on the left side or use the instructed knee-chest position. Insert gently toward the umbilicus, squeeze steadily and remain positioned at least 30 minutes, aiming to retain overnight. It can stain surfaces. For missed Canasa, use when remembered unless nearly time for the next dose; never use two together as compensation. Do not transfer that specific missed-dose instruction to an unreviewed formulation.

Evaluate renal function before treatment and periodically; reassess risk with kidney disease or nephrotoxic medicines and discontinue if renal function deteriorates. Selected labels give no verified creatinine-clearance dose-reduction table. Liver impairment requires individualized benefit/risk assessment because hepatic failure has occurred. Drink adequate fluids; do not invent a fixed fluid quota or uniform organ-adjustment algorithm.

Known or suspected hypersensitivity to salicylates, aminosalicylates or the selected product’s ingredients is contraindicated. Rowasa additionally specifically contraindicates sulfite hypersensitivity. Verify excipients instead of treating all mesalamine products as identical; a sulfite-free product requires its own verification.

These five selected U.S. mesalamine labels have no boxed warning. Serious renal, allergic, cutaneous and hematologic reactions remain important with oral and rectal use.

Oral trials reported headache, diarrhea, nausea, abdominal discomfort, flatulence and other product-specific effects. Canasa reports include dizziness, rectal pain, fever, rash, acne and colitis; Rowasa includes gas, flu-like symptoms, fever, joint/leg or rectal pain and hair loss. Pancreatitis, blood dyscrasias, renal/hepatic injury and severe allergic/skin events have been reported. Do not compare trial percentages across formulations as one common incidence.

NSAIDs and other nephrotoxic drugs can increase renal risk. Review OTC analgesics as well as prescriptions; monitor renal function and mesalamine-related effects. The label does not supply a universal percentage dose change.

Azathioprine, 6-mercaptopurine and other marrow-toxic medicines may increase blood dyscrasias or marrow failure. If combination treatment cannot be avoided, monitor CBC and platelet counts; do not assume rectal delivery exempts monitoring.

Avoid antacid coadministration with Apriso because granule-coating dissolution depends on pH; the label provides no numerical spacing interval that guarantees safety. Mesalamine can cause falsely elevated urinary normetanephrine with liquid chromatography/electrochemical detection; request an alternative selective assay when appropriate. This is not proof of a true biochemical abnormality.

Available pregnancy studies do not reliably establish a drug-associated risk; Canasa likewise describes insufficient data. Active ulcerative colitis itself is associated with adverse pregnancy outcomes, so discuss maternal treatment needs rather than stopping automatically. Mesalamine and its metabolite occur in milk in small amounts; infant diarrhea has been reported. Weigh breastfeeding benefits and maternal need, and monitor the infant for diarrhea. Different labels’ numerical milk summaries are not treated as one universal exposure estimate.

Lialda pediatric treatment is established at weight at least 24 kg with whole-tablet swallowing; underlying trial ages were 5–17, but the current indication is weight-based. Apriso, Pentasa, Canasa and Rowasa pediatric safety/effectiveness are not established; an evaluated Canasa pediatric study did not demonstrate efficacy. Older patients may have greater renal/comorbidity risk and blood dyscrasias: monitor CBC/platelets; consider the lower induction range with Lialda.

Absorbed drug/metabolite are substantially excreted renally. Follow kidney monitoring and stopping directions rather than inventing a dose table; liver disease also needs benefit/risk review. PKU matters specifically for Apriso phenylalanine, sulfite sensitivity for selected Rowasa and salicylate/aminosalicylate or other excipient allergy across products.

Mesalamine’s mechanism is not fully understood; a local anti-inflammatory effect on colonic epithelial cells is proposed, involving arachidonic-acid inflammatory pathways. It is not a systemic corticosteroid or antibacterial. Selected efficacy and dose schedules remain product- and disease-specific.

Oral systemic absorption differs: studied Lialda doses yielded approximately 21–22%, Apriso approximately 32%, and Pentasa 20–30%. Rectal absorption is variable and depends on the product and retention; Rowasa is largely excreted with subsequent bowel movements. Absorbed drug is acetylated in intestinal mucosa/liver and eliminated largely in urine as N-acetyl metabolite. Pentasa’s continued release prevents a simple oral elimination-half-life estimate; no universal half-life or milligram conversion is implied.

Review diagnosis/location, induction versus maintenance, product, weight/swallowing ability, kidney/liver disease and interacting medicines. Obtain renal assessment before and periodically during therapy; CBC/platelets are important in older patients and thiopurine combinations. Follow bleeding, stool symptoms and clinical/endoscopic response. Unusual headache or visual changes with Rowasa require immediate stopping/evaluation. No universal test interval or automatic flare-escalation algorithm is supplied.

Follow exact food, whole-tablet/capsule or approved sprinkle directions; do not crush a release system. Use rectal products only rectally and preserve specified retention. Maintain hydration, avoid relevant sun exposure, and report severe rash, chest symptoms, kidney-stone symptoms or worsening bloody diarrhea. Drug/metabolite contact with hypochlorite bleach may discolor urine reddish-brown after leaving the body; report urine already discolored during flow rather than assuming every change is benign.

Seek clinician/Poison Control assessment for overdose or wrong-route/product administration; confusion, seizures, rapid breathing, tinnitus or severe systemic symptoms require urgent care. There is no specific mesalamine antidote; clinical treatment addresses salicylate-like toxicity, fluids, electrolytes and renal function. Do not attempt home decontamination or an unverified substitution.

Product

Lialda 1.2 g delayed-release tablet

Route

Oral; prescription only

Appearance

Red-brown ellipsoidal; S476 imprint

Example package

120 tablets · NDC 54092-476-12

Lialda: 1.2 g delayed-release tablets. Apriso: 0.375 g extended-release capsules, light blue with G/M on either side of a black band; 120-capsule NDC 65649-103-02. Pentasa: 250 and 500 mg extended-release capsules. Canasa: 1000 mg light tan to grey bullet-shaped rectal suppository; 30-unit NDC 58914-501-56. Rowasa: 4 g / 60 mL off-white to tan rectal suspension; 7-bottle NDC 0037-0066-05. Other release systems and sulfite-free products are outside the reviewed prescribing scope.

Lialda: 15–25°C, excursions to 30°C. Apriso: 20–25°C, excursions 15–30°C. Pentasa: 25°C, excursions 15–30°C. Canasa: below 25°C, refrigeration permitted; protect from direct heat, light and humidity. Rowasa: 20–25°C, excursions 15–30°C; once the seven-bottle foil unit is opened, use promptly as directed. Slight darkening does not affect potency, but discard dark-brown contents. Follow the actual carton; do not invent an opened-product discard interval.